Furthermore, EGFR variant status is being evaluated in NSCLC patients using the ddPCR method in ongoing clinical trials, suggesting that liquid biopsy can play a major role in guiding treatment decisions for NSCLC patients [194]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.